Semaglutide vs AOD-9604: Head-to-Head Comparison
Semaglutide is an FDA-approved blockbuster for obesity with robust clinical evidence, while AOD-9604 is a fragment of human growth hormone (hGH 177-191) with limited and disappointing clinical trial results. AOD-9604 failed to outperform placebo in Phase IIb/III obesity trials.
Side-by-Side Comparison
| Dimension | Semaglutide | AOD-9604 |
|---|---|---|
| Evidence Level | Phase III trials, FDA-approved, extensive real-world data | Failed Phase IIb/III trials for obesity |
| FDA Status | FDA-approved for obesity and T2D | Not approved; GRAS status for food use only in Australia |
| Mechanism | GLP-1 receptor agonist, appetite suppression, gastric slowing | hGH fragment stimulating lipolysis without IGF-1 increase |
| Weight Loss Efficacy | 15-17% in clinical trials | No significant difference from placebo in Phase III |
| Side Effects | GI side effects, potential thyroid concerns | Minimal reported side effects |
| Cost | Very high (branded pharmaceutical) | Low to moderate (research peptide) |
Peptide Overviews
Semaglutide
AFDA ApprovedSemaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.
AOD-9604
CPreclinicalAOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) originally developed for obesity treatment. It received GRAS status from the FDA for use in food products.
Semaglutide vs AOD-9604: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.